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Procedures using real-time technique were developed to demonstrate the presence of herpes simplex virus
type 1 (HSV-1) and HSV-2, varicella zoster virus (VZV), and cytomegalovirus (CMV) in miscellaneous clinical
specimens. The assays were compared to rapid culture using centrifugation followed by detection with mono-
clonal antibodies. A total of 711 consecutive samples were collected from different patient groups. Throat swabs
were obtained from transplant patients; dermal or oral specimens were collected from patients suspected for
VZV or HSV infection. Genital specimens were taken from patients who attended the Clinic for Sexually
Transmitted Diseases at the Dijkzigt Hospital Rotterdam presenting with symptoms of a primary genital ulcer.
Nucleic acid extraction was carried out using a MagnaPure LC instrument. The amplification steps were
performed on the ABI Prism 7700 sequence detection system. To monitor the process of extraction and
amplification, a universal control consisting of seal herpesvirus type 1 (PhHV-1) was added to the clinical
specimens. By culture 127 of 668 (19%) samples were positive for HSV-1, 72 of 668 (10.8%) specimens were
positive for HSV-2, and 17 of 366 (4.6%) were positive for VZV. Using real-time amplification the numbers of
positive specimens were 143 of 668 (21.4%), 97 of 668 (14.5%), and 27 of 366 (7.4%), respectively. Eighty-six
specimens were tested for CMV, 12 (14.0%) were positive by culture, and 17 (19.8%) were positive by real-time
PCR. The clinical data of the patients with discrepant results were reviewed thoroughly. In all cases the
patients with only real-time PCR-positive results could be considered as truly infected. We concluded that the
real-time amplification technique is suitable for the detection of human herpesvirus infection. It offers a
semiquantitative and reliable assay with a quick result that is more sensitive than rapid culture, especially for
the diagnosis of HSV-2 and VZV infections.
Standard laboratory technique for the detection of herpes-
virus infection is cell culture and the recognition of a cyto-
pathic effect followed by unequivocal serological identification
of the virus involved. Modifications of the cell culture tech-
nique by centrifugation of the inocula on the cell monolayers
and the use of immunofluorescence techniques provide a more
rapid detection. Nevertheless, sensitivity of detection of the
herpes simplex viruses (HSVs) (HSV type 1 [HSV-1] and
HSV-2) can be improved by implementing amplification tech-
niques (1, 2, 3, 4, 6, 10, 11). Increased sensitivity of the labo-
ratory diagnosis of varicella zoster virus (VZV), another mem-
ber of the herpesvirus family, has also been reported, when
using DNA amplification (5, 10). For the diagnosis of human
cytomegalovirus (HCMV) infection, molecular techniques es-
tablishing viral loads in serum or plasma have largely replaced
culture-based techniques (8). However, the clinical value of
amplification techniques compared to culture using centrifu-
gation and immunofluorescence for the detection of HCMV in
other specimen’s remains to be assessed.
The implementation of molecular techniques in diagnostic
virology has made a step forward by the availability of semi-
automated extraction systems, as well with the introduction of
real-time technology. This has produced a substantial reduc-
tion in throughput time, as well as limiting the time needed to
handle the samples. Furthermore, real-time technologies en-
able one to quantify the results. Quantification of viral se-
quences in the specimens can provide more insight into the
clinical significance of the presence of the detected virus. In
this study, our goal was to compare culture techniques for the
detection of HSV, VZV, and HCMV with a real-time ampli-
fication technique, allowing (relative) quantification of the vi-
ruses in the clinical material. Furthermore, with the introduc-
tion of a universal and nonhuman viral control, i.e., seal
herpesvirus type 1 (PhHV-1), an accurate control for monitor-
ing the process from extraction through amplification became
feasible (9).
MATERIALS AND METHODS
Patients and clinical samples. A total of 711 specimens were included from
November 2000 through June 2001. Anogenital samples (n 161) were collected
from patients attending the Clinic for Sexually Transmitted Diseases at the
Dijkzigt Hospital Rotterdam. Dermal specimens (n  116), ocular swabs (n 
27) and specimens from the oral region (n  403), and bronchoalveolar lavage
samples (n  4) were collected from different patient groups. The specimens
from the oral region consisted of 275 throat swabs that were taken from trans-
plant patients (heart, liver, kidney, or bone marrow) who were screened for
HCMV disease; and in case of ulcerative lesions specimens of the mouth or lips
(n  128) were collected. The dermal specimens were taken from clinical lesions
suspected for HSV or VZV infection. Lastly, the 27 ocular swabs were taken in
case of possible herpes keratitis or conjunctivitis. All specimens but the bron-
choalveolar lavage fluid specimens were collected in virus transport medium
consisting of minimal essential medium-HEPES balanced salt solution (BioWhit-
taker, Verviers, Belgium) supplemented with 10% fetal bovine serum, penicillin
(100 U/ml), streptomycin (100 g/ml), and amphotericin B (2.5 g/ml).
Culture technique. Monolayers of human embryonic lung fibroblasts were
cultured in 24-well microtiter plates. For each virus to be detected, 200 l of the
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sample was inoculated in duplicate, and plates were centrifuged at 3,500  g for
15 min at room temperature. After 48 h, one part of the cells was incubated with
monoclonal antibodies against HSV-1 or HSV-2 (De Beer Medicals, Uden, The
Netherlands, and Imagen, Dako Diagnostics, Cambridgeshire, United Kingdom)
or VZV or CMV (Argene-Biosoft, Varilhes, France) separately. The other part
of the cell culture was maintained for another 14 days. When a cytopathic effect
was observed, cells were incubated again with the monoclonal antibody specific
for the agent related to the typical cytopathic effect.
Nucleic acid extraction. For the isolation of nucleic acids from the original
clinical material, the MagnaPure LC Isolation station (Roche Applied Science,
Penzberg, Germany) was used. Briefly, 200 l of material was isolated in dupli-
cate using the Total Nucleic Acid isolation kit (Roche Applied Science) exactly
as described by the manufacturer. The nucleic acid was resuspended in a final
volume of 100 l. To monitor the whole process from isolation of nucleic acids
until real-time detection, a universal internal control was used. This internal
control sample consisted of a whole-virus preparation of a seal herpesvirus
(PhHV-1), which was added to the original clinical sample at a final concentra-
tion of approximately 5,000 to 10,000 DNA copies per ml, equivalent to a
threshold cycle (Ct) value of approximately 30 in the real-time detection system
used (9).
Real-time TaqMan assay. The amplification tests were performed as individ-
ual assays for each virus. Multiplex amplification was not performed, as this
resulted in a loss of sensitivity (data not shown). Primers for the detection of
HSV-1 and VZV were published before (10, 11). The sequences for HSV-2,
CMV, and PhHV-1 were designed using Primer Express software (Applied
Biosystems, Nieuwerkerk aan de IJssel, The Netherlands). The sequences of the
primers and the probes used, and the location of the genes from which they were
derived, are listed in Table 1. All PCR amplification reactions were performed in
a 50-l volume containing 2 TaqMan Universal Mastermix (Applied Biosys-
tems), forward primer (45 pmol/l), 2.5 pmol of reverse primer, 5 pmol of
TaqMan probe, and 20 l of isolated DNA. The reactions were carried out in a
96-well plate, which was centrifuged for 1 min at 1,000  g at room temperature
in a swing-out rotor (Rotina 48R; Hettich, Tuttlingen, Germany) to remove small
air bubbles in the reaction vessels. The amplification and detection was per-
formed with an ABI Prism 7700 sequence detection system (Applied Biosys-
tems). After incubation for 2 min at 50°C with uracil N-glycosylase to inactivate
possible PCR contaminants from former reactions, the reaction tube was incu-
bated for 10 min at 95°C to inactivate the uracil N-glycosylase and to release the
activity of the AmpliTaq Gold DNA polymerase. The PCR cycling program
consisted of 42 two-step cycles of 15 s at 95°C and 60 s at 60°C. Real-time
measurements were taken, and a Ct value for each sample was calculated by
determining the point at which the fluorescence exceeded a background limit of
0.04. Each run contained several negative controls (no template), and a positive
control containing a known viral copy number based on a standard counted by
electron microscopy (EM) when available. Each specimen was isolated and
amplified in duplicate and only considered positive if both replications were
above the threshold limit.
Standardization and quality control (QC). For the standardization of the
HCMV and HSV-1 and HSV-2 real-time detection assays, an EM-counted
standard (Advanced Biotechnologies Incorporated) was used. Dilutions ranging
from 10 million down to 10 copies per ml were made to characterize linearity,
precision, specificity, and sensitivity of the TaqMan assay. For VZV and
PhHV-1, such a standard is not available. For these viruses, the standard curves
generated were extrapolated on the basis of the curves made for HSV-1 and -2.
To determine the performance of detection for HSV-1 and -2, we participated
in the European Union (EU) Concerted Action of QC of Nucleic Acid Ampli-
fication program.
Statistics. Epi Info 6.02 (Centers for Disease Control and Prevention, Atlanta,
Ga.) was used to calculate the characteristics of the different assays compared.
The means of the TaqMan test results and their differences with 95% confidence
intervals were calculated using confidence interval analysis (7).
RESULTS
QC. To enable accurate monitoring of the amplification
steps combined with automated extractions, we included a
universal control in each clinical sample before the extraction
was started. This consisted of a seal herpesvirus (PhHV-1)
which was added at a low concentration to each sample. This
internal viral control agent was isolated and amplified in each
sample, and this standard provided a measurement for the
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precision and reproducibility of the assays (mean Ct value,
30.7; coefficient of variation, 3.2% [data not shown]). In case
the Ct value of the internal control virus exceeded 32.7 (mean
 2 standard deviations), it was assumed that inhibition or loss
of sample had occurred. The whole procedure was then re-
peated, and in most cases, the results were within the expected
range. It was established that in 0.52% of the clinical samples,
no amplification product could be detected in duplicate ali-
quots. These samples were therefore classified under the head-
ing “no amplification possible” and excluded from the analysis.
The cause of these undetectable results was not determined.
To determine the detection limits of the amplification reac-
tions, data generated using dilution series of available EM
standards were used. However, for the detection of CMV it
was shown that the amount counted by EM must be an under-
estimation, since dilutions down to 0.1 copy per reaction were
always detected (results not shown). More-accurate data were
observed using the EM-quantified viral stocks of HSV-1 and
-2. Participation in the EU QC program determined the lower
detection level for these two viruses: 580 copies per ml for
HSV-1 and 430 copies per ml for HSV-2.
Clinical samples. A total of 711 samples were included in
the study. Of these, 668 samples were processed for the detec-
tion of HSV. For the presence of HCMV, 86 specimens were
screened. Detection of VZV was carried out on clinical indi-
cation in 366 specimens.
By culture 127 of 668 (19%) samples were positive for
HSV-1 and 72 of 668 (10.8%) specimens were positive for
HSV-2. HCMV was found by culture in 12 of 86 (14.0%)
specimens, and 17 of 366 (4.6%) were positive for VZV. By
real-time amplification the number of specimens positive for
HSV-1 was 143 of 668 (21.4%) and the number positive for
HSV-2 was 97 of 668 (14.5%). By real-time PCR 17 of 86
(19.7%) specimens were positive for CMV and 27 of 366
(7.4%) were positive for VZV. These results are summarized
in Table 2.
The samples showing discrepant results were retested in
both assays when sufficient material was available. A total of 24
(20 only PCR positive) remained discrepant for HSV-1, 27 (26
only PCR positive) remained discrepant for HSV-2, 7 (6 only
PCR positive) remained discrepant for CMV, and 12 (11 only
PCR positive) remained discrepant for VZV. Subsequently,
the clinical data of the patients with discrepant results were
reviewed. Based on results from previously or subsequently
collected samples the majority of the PCR-positive but culture-
negative specimens could be considered to be true positives. Of
the 20 patients whose specimens were HSV-1 cell culture neg-
ative and positive by PCR, 12 were known to be latently in-
fected with HSV-1, and 3 of the 4 patients whose specimens
were HSV-1 cell culture positive and negative by PCR were
known to be latently infected with HSV-1. With regard to
HSV-2, 14 of the 26 patients whose specimens were HSV-2 cell
culture negative and positive by PCR were patients with doc-
umented recurrences of genital herpes. One patient suffered
from a herpes keratitis. With regard to CMV, six samples were
positive for CMV only by real-time PCR. Two specimens were
collected from patients for whom samples taken from other
sites were also positive for CMV; three samples were double
infected with HSV. It is conceivable that in cell culture of
specimens containing both HSV and CMV, the latter virus may
not be detected due to the more rapidly growing HSV. Lastly,
all 11 specimens positive for VZV only by PCR were obtained
from patients with clinical symptoms of a primary infection or
a reactivation of VZV, including two patients with neurological
symptoms such as facial paresis and a vesicle on the tympanic
membrane. The one discrepant specimen shown to contain
HSV-2 by PCR, and in which cell culture identified VZV, was
collected from an anal lesion. The clinical presentation of the
lesion was typical of anogenital herpes rather than of a solitary
VZV eruption.
As we did not define an extended “gold standard,” we cal-
culated the test characteristics of the real-time PCR using the
cell culture as standard and vice versa. The results are shown in
Tables 3 and 4. Compared to the cell culture as the standard,
the real-time PCR is sensitive but also less specific for detect-
ing HSV-1, HSV-2, HCMV, and VZV. When the real-time
PCR is taken as the standard, the cell culture is much less
sensitive for the detection of VZV, HCMV, HSV-2, and, to a
lesser extent, HSV-1.
TABLE 2. Detection of HSV, CMV, and VZV by rapid
culture and real-time PCR
Virus Real-timePCR result
No. of specimens
with result by
rapid culture using
immunofluorescence
Total no. of
specimens
Positive Negative
HSV-1 Positive 123 20 366
Negative 4 521 525
Total 127 541 668
HSV-2 Positive 71 26 97
Negative 1 570 571
Total 72 596 668
CMV Positive 11 6 17
Negative 1 68 69
Total 12 74 86
VZV Positive 16 11 27
Negative 1 338 339
Total 17 349 366
TABLE 3. Test characteristics of real-time PCR according to
virus culture with immunofluorescence as standard
Virus
No. of specimens with test result/no. of specimens
with result by standard (%)
Sensitivity Specificity PVPTa PVNTb
CMV 11/12 (91.7) 68/74 (91.1) 11/17 (64.7) 68/69 (98.6)
VZV 16/17 (94.1) 338/349 (96.8) 16/27 (59.3) 338/339 (99.7)
HSV-1 123/127 (96.9) 521/541 (96.3) 123/143 (86.0) 521/525 (99.2)
HSV-2 71/72 (98.6) 570/596 (95.6) 71/26 (73.2) 570/571 (99.8)
a PVPT, predictive value positive test.
b PVNT, predictive value negative test.
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Viral loads. We determined whether the viral load in the
clinical sample could explain the differences between the re-
sults of the real-time PCR and cell culture, assuming that the
viral load is correlated with the amount of infectious virus.
Since the viral load in the sample can be relatively assessed by
the Ct value, we compared these values for the samples that
were cell culture positive with values for the samples that were
cell culture negative. High Ct values are representative of a low
viral load, while a low Ct value reflects a high viral load. In all
cases the culture-positive samples had a lower Ct value than
the culture negative samples. The differences for the mean Ct
values were statistically significant for VZV (4.57; 95% con-
fidence interval, 9.00 to 1.29), HSV-1 (7.77; 95% confi-
dence interval, 10.7 to 4.79), and HSV-2 (10.5; 95% con-
fidence interval, 12.6 to 8.39). The results are shown in
Table 5.
Double infection. Using real-time PCR, 11 double infections
could be detected, while cell culture yielded only 1 of these
double infections. The following combinations were found:
HSV-1–HSV-2 (four times), HSV-1–CMV (three times), HSV-
2–CMV (one time), and HSV-1–VZV (three times).
DISCUSSION
In this prospective study, real-time amplification techniques
were compared with the rapid cell culture technique for the
detection of herpesviruses in samples collected from genital,
dermal, and oropharyngeal lesions. The real-time PCR ap-
peared to be a more sensitive assay than cell culture for the
detection of all four herpesviruses studied.
Whenever a new technique is more sensitive than a previ-
ously used one, it is important to look in detail at the clinical
relevance of the specimens that are solely positive by this new
technology, in order to assess the specificity of the newer assay.
Definition of an expanded gold standard using a third tech-
nique seems to have advantages. However, then the question
arises whether this technique has been validated and why this
assay can be considered to be a reliable test to be used as a
decisive judge. Detailed analysis of the patients whose samples
yield discrepant results revealed that the majority of the PCR-
only-positive results were probably truly positive results. The
specificity of the real-time PCR assays was also tested by ap-
plying the tests on cell cultures of other viruses that can be
expected to be present in the samples that were collected. All
primer sets were specific for the intended target (data not
shown).
The predictive value of a test is dependent on the prevalence
of the disease in the population. In fact, all specimens except
the throat swabs that were collected to screen for CMV were
obtained from patients with lesions. Therefore, the samples
with test results solely positive by real-time PCR were obtained
from patients with relevant symptomatic disease; consequently,
the predictive value of a positive test result relative to disease
was high. It must be noted that the predictive value of a
positive PCR test in comparison with the cell culture as gold
standard was rather low, only because the cell culture was
more often negative for samples collected from patients with
symptomatic disease. As few patients without lesions were
included in the study, the predictive values of a negative test
result excluding disease might be different when determined in
populations with differing prevalences of the conditions in
question. An exception can be made for the throat swabs
collected in this study, because these swabs were taken from
transplant patients in order to monitor CMV activity regard-
less of the presence of symptoms. In fact, monitoring CMV
disease in these patients can be carried out preferably by test-
ing plasma specimens or peripheral blood mononuclear cells
(8).
In other studies detection of HSV by amplification tech-
niques turned out to be more sensitive than cell culture, espe-
cially for HSV-2 and VZV (2, 4, 5, 6). In particular for VZV,
the viral load of the culture-negative specimens as represented
by the low Ct value was relatively high, indicating the presence
of high levels of VZV DNA and the instability of the virus
and/or the presence of incomplete, noninfectious virus.
The MagnaPure LC system proved to be a reliable and
standardized system for extracting nucleic acids from the der-
mal, genital, and throat specimens collected in virus transport
medium, as has been described previously by Espy et al. (6).
An advantage of the closed real-time PCR is the lack of con-
tamination during processing, since the reaction tubes do not
need to be opened for the detection step (10). The addition of
the PhHV DNA as an exogenous internal control provided the
evidence that negative results were real negatives and not
caused by inhibition. For a low proportion of the specimens the
TABLE 5. Ct values of real-time PCR according to virus and
culture-immunofluorescence result
Virus and
culture
result
No. of
speci-
mensa
Ct value Difference
between sample
means (95% confi-
dence interval)
P
Mean SD
CMV
Positive 10 33.1 6.25 2.14 (8.39–4.12) NSb
Negative 6 36.3 4.35
VZV
Positive 15 19.5 4.75 4.57 (9.00–1.29) 0.01, 0.05
Negative 11 24.1 5.95
HSV-1
Positive 125 27.0 6.33 7.77 (10.7–4.79) 0.01
Negative 19 34.8 4.25
HSV-2
Positive 72 23.2 4.35 10.5 (12.6–8.39) 0.01
Negative 25 33.7 5.16
a Some specimens are missing Ct data.
b NS, not significant.
TABLE 4. Test characteristics of virus culture-immunofluorescence
with real-time PCR as standard
Virus
No. of specimens with test result/no. of specimens
with result by standard (%)
Sensitivity Specificity PVPTa PVNTb
CMV 11/17 (64.7) 68/69 (98.6) 11/12 (91.7) 68/74 (91.9)
VZV 16/27 (59.3) 338/339 (99.7) 16/17 (94.1) 338/349 (96.8)
HSV-1 123/143 (86.0) 521/525 (99.2) 123/127 (96.9) 521/541 (96.3)
HSV-2 71/97 (73.2) 570/571 (99.8) 71/72 (98.6) 570/596 (95.6)
a PVPT, predictive value positive test.
b PVNT, predictive value negative test.
VOL. 41, 2003 HERPESVIRUS CULTURE AND REAL-TIME PCR 579
nucleic acid extraction had to be repeated to remove inhibiting
substances. Of importance is the determination of the lower
detection level of the real-time amplification test developed.
The introduction of internationally active QC programs for
viral diagnostic assays is important to validate the assays that
laboratories develop in-house. Initiatives from the EU QC
program (now taken over by the QC for Molecular Diagnostics
program), endorsed by organizations such as the European
Society for Clinical Virology and the European Society for
Clinical Microbiology and Infectious Diseases, are instrumen-
tal to implement better-defined standard assays. Furthermore,
the introduction of internal controls into each clinical sample
increases the true value of the results generated. Technologies
that fulfill these requirements are currently available and
should be mandatorily introduced with each in-house devel-
oped assay that is used in clinical diagnostics.
In our laboratory setting, the rapid cell culture inoculation of
the monolayers is performed each working day shortly after
arrival of the specimens; after 48 h the detection of viral anti-
gens is executed, and positive test results are reported to the
clinician. The automated nucleic acid extraction is also com-
menced every working day and carried out in the afternoon or
overnight. The amplification step is performed the next morn-
ing. All real-time PCR results are available within 24 h after
arrival at the laboratory whether they are positive or negative,
except during weekends. The mean time to produce a positive
result by cell culture was 5.9 days (range, 1 to 20 days), includ-
ing weekends and holidays, while the mean time to release a
negative result to the clinician was 15.7 days (range, 13 to 24
day). The advantage of the real-time PCR relative to the speed
of reporting both a negative as well as a positive result to the
clinician is therefore obvious.
We did not execute an extensive cost comparison. In The
Netherlands, a fixed price can be charged for laboratory tests.
The price for a rapid cell culture using three different mono-
clonal antibodies is approximately 47.00 euros (without doc-
tors’ fee), and the price for four PCR tests (three diagnostic
targets and one for the internal control) using an automated
system is about 83.00 euros. However, the prices for the com-
mercially available components of nucleic acid extraction and
for the real-time PCR are decreasing rapidly. At the time of
writing, in our situation the price for the reagents of one
nucleic acid extraction with the MagnaPure instrument to-
gether with the reagents needed for four real-time PCRs is
approximately 15.00 euros. We expect that in the near future
the total costs for nucleic acid extraction and the subsequent
real-time PCR tests will be comparable with the costs for rapid
cell culture.
In conclusion, real-time amplification technique in combi-
nation with automated nucleic acid extraction is suitable for
the detection of human herpesviruses HSV-1, HSV-2, VZV,
and HCMV in specimens collected from genital, dermal, oral,
and oropharyngeal lesions. In comparison to rapid culture, this
real-time method is a rapid, more sensitive, semiquantitative,
and reliable assay.
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